Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + cisplatin with PD-1 inhibitor as adjuvant therapy for urothelial carcinoma
ChiCTR2300067691Phase 4Not yet recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of gemcitabine and cisplatin in transitional cell carcinoma of the bladder (TCC) (2 arms), sponsored by The Second Hospital of Tianjin Medical University. Primary endpoints: Disease-free survival and Safety evaluation. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
gemcitabinecisplatin
03
Conditions
transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on ChiCTR2300067691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300067691.